Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,180
- 主要终点
- To assess the difference in asthma related exacerbations
研究概览
简要总结
The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 12 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with asthma as determined by ICD-9 codes and asthma drug use
- •at least 12 years of age
- •treated with inhaled corticosteroids
排除标准
- •Subjects with COPD or treatment for COPD
研究组 & 干预措施
Asthma patients treated with inhaled corticosteroids
Asthma subjects newly prescribed inhaled corticosteriods
干预措施: Fluticasone propionate/salmeterol combination (Drug)
Asthma patients treated with inhaled corticosteroids
Asthma subjects newly prescribed inhaled corticosteriods
干预措施: Inhaled corticosteroids (Drug)
结局指标
主要结局
To assess the difference in asthma related exacerbations
时间窗: 90 days post index
Asthma related exaceberation is defined as any asthma related emergency department visit, or inpatient visit or oral corticosteroid dispensing.
次要结局
未报告次要终点